alexa Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology.
Psychiatry

Psychiatry

Clinical Depression

Author(s): Pllabauer EM, Petermann R, Ehrlich HJ

Abstract Share this page

Abstract A conjugate vaccine comprised of de-O-acetylated group C meningococcal polysaccharide coupled to tetanus toxoid (GCMP-TT) has been licensed in 32 countries and incorporated in a comprehensive UK vaccination program. Extensive evidence, forming the subject of this meta-analysis, has rapidly accumulated on the immunogenicity, safety and posology of GCMP-TT as well as its epidemiological impact. GCMP-TT has been shown effective after a single dose in individuals >12 months of age, and initial posology specified three doses in infants. However, based on a recent clinical trial, posology was reduced to two doses in infants. Pooled protection rate, defined as proportion of subjects with serum bactericidal antibody (SBA) levels > or = 1:8, was 99.4\% (CI, 98.2-99.9\%) in seven clinical trials covering all age groups. Robust responses to GCMP-TT have been demonstrated with respect to SBA, IgG levels and antibody avidity. In post-marketing pharmacosurveillance encompassing >12 x 10(6) GCMP-TT doses distributed worldwide, the vaccine has been well tolerated with an incidence rate of 0.01\% for all the most commonly encountered types of adverse events. After a catch-up UK vaccination campaign where 5-8 year old children were primarily given GCMP-TT, a 93\% decline in meningococcal disease incidence was observed. In view of its immunogenicity, safety and potential suitability for use among infants in reduced dose schedules, GCMP-TT appears to mark a major advance over predecessor polysaccharide vaccines for the prevention of meningococcal C disease.
This article was published in Hum Vaccin and referenced in Clinical Depression

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords